Cooper Companies (The)

CooperVision has multiple, mutually reinforcing advantages. Efficient scale and cost advantages: high fixed costs, automation, and validated processes in silicone hydrogel dailies and torics create meaningful barriers; we score this 80/100 and weight it 30%.

Intangibles: brand trust with eye‑care practitioners and a growing evidence base around MiSight support premium positioning; 75/100, weight 20%. Switching costs: moderate for consumers but higher for practitioners who standardize fittings and inventory; 65/100, weight 25%. Network effects: minimal; 10/100, weight 5%.

Regulatory and quality systems: approvals, ISO/QMS and MDR compliance constitute a barrier but require ongoing spend; 70/100, weight 20%.

Weighted across components yields ~72. Durability is strongest in CooperVision; however, the CooperSurgical portfolio’s moat is narrower and recently challenged by quality events and litigation, which trims the consolidated score. FY25 segment data showing CVI margin of 27% vs CSI 3% supports the asymmetry in moat quality.